Inno√Fin
EU Finance for Innovators

A new generation of financial instruments and advisory services by the European Commission and the European Investment Bank Group to help innovative firms access finance in the EU and beyond.
What is InnovFin?

Under Horizon 2020, the EU Research and Innovation programme for 2014-20, “InnovFin – EU Finance for Innovators” offers a range of tailored products which provide financing to support research and innovation by companies - large and small, young and old - and to support promoters of research infrastructure.

InnovFin supports activities, which by their nature are riskier and harder to assess than traditional investments, and therefore often face difficulties in accessing finance. All are demand-driven instruments, with no prior allocations between sectors, countries or regions. Firms and other entities located in EU Member States and Horizon 2020 Associated Countries are eligible to become final beneficiaries. Typically, the EIB provides between 35% and 50% of the project or investment cost and is often key in attracting other investors from the public or private sector.

The EIB assesses the eligibility of the company and/or the project, technological and economic viability and environmental soundness, as well as the promoter’s financial situation and outlook. Subject to the completeness of the information available and the nature of the financing, the time between a first contact with the EIB and the signature of a financing contract takes approximately six months.
InnovFin in figures*

**EIB**

- **110** innovative projects and companies
- **90 000** jobs supported
- **EUR 7.4 bn** of financing provided by the European Investment Bank

**EIF**

- **Over 11 000** innovative early-stage enterprises, SMEs and small midcaps
- **Close to 500 000** jobs supported
- **EUR 6.8 bn** of financing provided by the European Investment Fund

**Total EIB innovation investment by sector**

- Industry & Manufacturing: 34%
- Education: 25%
- Telecommunications: 15%
- SMEs & Midcaps: 10%
- Research infrastructure: 8%
- Services: 6%
- Urban development and construction: 2%

* As at end 2017
** Innovation investments by the EIB, including but not limited to InnovFin, 2014-2017
The InnovFin product range consists of a suite of tailored financial instruments. Whatever the size and stage of the project, we can find a suitable match.

**InnovFin Technology Transfer** targets investments in technology transfer funds, focusing on pre-seed (including proof of concept) and seed stages, especially in areas of key enabling technologies (including—but not limited to—ICT, nanotechnology, biotech, cleantech, and medtech) and other Horizon 2020 objectives, such as promotion of intellectual property, licensing and spin off activities.

**InnovFin Business Angels** targets investments in business angel managed funds or co-investment funds.

**InnovFin Venture Capital** targets investments in venture capital funds that provide funding to enterprises in their early-stage operating phase.

**InnovFin Fund-of-Funds** Including funding to the separately managed Pan-European Venture Capital Fund(s)-of-Funds Programme.

**InnovFin SME Guarantee** improves access to finance by making debt financing available to innovative small and medium-sized enterprises and small midcaps (up to 499 employees).

**InnovFin Emerging Innovators** bridges the research and innovation (R&I) investment gap in Moderate and Modest Innovator EU Member-States (per the European Innovation Scoreboard) and Horizon 2020 Associated Countries.

**InnovFin MidCap Guarantee** makes debt financing available to innovative mid-caps (up to 3000 employees) which are not eligible under InnovFin SME Guarantee.

**InnovFin Corporate Research Equity** increases the supply of equity-type financing under the European Fund for Strategic Investment to large R&I programmes and to innovative large midcaps.

**InnovFin Science** supports R&I investment by research institutes, universities and public or private research organisations.

**InnovFin Energy Demonstration Projects** involves projects in the fields of energy system transformation, such as renewable energy technologies, smart energy systems, energy storage, carbon capture and storage, or carbon capture and use.
InnovFin Thematic Investment Platforms.
InnovFin Circular Bioeconomy Investment Platform will be the first thematic investment platform. This platform will be managed by a financial intermediary / fund manager to be selected through an open call for expression of interest.

InnovFin Advisory aims to improve the ‘bankability’ and investment-readiness of large projects that need substantial, long-term investments. It also provides advice to improve the conditions for access to risk finance for R&I and advises on the set-up of thematic investment platforms. The main clients foreseen are promoters of large R&I projects that meet Horizon 2020’s Societal Challenges. InnovFin Advisory has a large portfolio of horizontal activities and a strong track record in advising innovative companies to enhance access to EIB and / or other financing.

Infectious Diseases Finance Facility is for developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combating infectious diseases. Project costs may include clinical trial costs, set-up of commercialization, such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.

InnovFin Thematic Investment Platforms: InnovFin Circular Bioeconomy Investment Platform will be the first thematic investment platform. This platform will be managed by a financial intermediary / fund manager to be selected through an open call for expression of interest.

---

<table>
<thead>
<tr>
<th>Corporate</th>
<th>Science</th>
<th>Thematic Finance</th>
<th>Advisory</th>
</tr>
</thead>
<tbody>
<tr>
<td>InnovFin Emerging Innovators</td>
<td>InnovFin Science</td>
<td>InnovFin Energy Demo Projects</td>
<td>InnovFin Advisory</td>
</tr>
<tr>
<td>InnovFin MidCap Guarantee</td>
<td></td>
<td>InnovFin Infectious Diseases</td>
<td></td>
</tr>
<tr>
<td>InnovFin Corporate Research Equity</td>
<td></td>
<td>InnovFin Thematic Investment Platforms</td>
<td></td>
</tr>
</tbody>
</table>

- SMEs, Midcaps, Large Caps, SPVs
- Research Institutes, Universities, Research Organisations
- SMEs, Midcaps, possibly Large Caps, SPVs
- Public and Private Sector Promoters
- Financial Advisory

Direct or Indirect products

InnovFin MidCap Growth Finance is deployed under the European Fund for Strategic Investments (EFSI) since November 2016.

---

Infectious Diseases Finance Facility

is for developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combating infectious diseases. Project costs may include clinical trial costs, set-up of commercialization, such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement.

InnovFin Thematic Investment Platforms:
InnovFin Circular Bioeconomy Investment Platform will be the first thematic investment platform. This platform will be managed by a financial intermediary / fund manager to be selected through an open call for expression of interest.

InnovFin Advisory aims to improve the ‘bankability’ and investment-readiness of large projects that need substantial, long-term investments. It also provides advice to improve the conditions for access to risk finance for R&I and advises on the set-up of thematic investment platforms. The main clients foreseen are promoters of large R&I projects that meet Horizon 2020’s Societal Challenges. InnovFin Advisory has a large portfolio of horizontal activities and a strong track record in advising innovative companies to enhance access to EIB and / or other financing.
We have financed some truly ground-breaking inventions to the tune of **EUR 14bn**. So far, more than **110** projects and over **11,000** small and early-stage enterprises have benefited – from small tech start-ups to large research facilities and circular economy companies.

1. **PORTUGAL**

**Biosurfit**  
EUR 12m  
Revolutionises medical diagnostics with technology that allows doctors to get the blood-test results in a matter of minutes from a single drop of blood.

2. **NETHERLANDS**

**Ultimaker**  
EUR 15m  
Customises prosthetics for amputees in the developing world using a 3D printer.

3. **FINLAND**

**AW-Energy**  
EUR 10m  
Established by a professional diver who witnessed first-hand the power of waves, the company’s converters transform the energy of the sea into electricity.

4. **GERMANY**

**Heliatek**  
EUR 20m  
The firm produces an organic, transparent photovoltaic solar film which can be sandwiched between layers of glass in office windows or integrated into facades of industrial buildings to produce solar energy.

5. **FRANCE**

**Qwant**  
EUR 25m  
A European search engine that guarantees the privacy of its users and only provides non-violent content to young children.

6. **SPAIN**

**Stat-Dx**  
EUR 20m  
Molecular diagnostics in one hour, allowing doctors to use more effective treatments and potentially reducing the use of antibiotics.

7. **SLOVENIA**

**Gorenje**  
EUR 50m  
Research and development in domestic appliances, including increasingly environmentally responsible products.

8. **SWEDEN/DENMARK**

**European Spallation Source**  
EUR 100m  
International scientific research infrastructure in Lund, Sweden, and in Copenhagen. With neutron beams one hundred times brighter than current facilities, this project uses neutron-scattering techniques that offer the possibility of monitoring material structures and motion at a molecular level. It opens up new opportunities for researchers in multiple disciplines such as life sciences, environment, energy, transport and engineering, as well as physics, chemistry and even archaeology.

9. **UK**

**NetThings**  
With the help of the European Investment Fund, Barclay’s was able to finance this Edinburgh-based firm developing a platform for controlling things like heating, water, electricity and security over the internet.
TOFAS
EUR 55m
R&I activities for one of Turkey’s main car manufacturers, to enhance the fuel efficiency and safety characteristics of motor vehicles.

CZECH REPUBLIC
Frusack
EUR 50m
This SME offers an environmentally-sustainable solution for carrying groceries, producing reusable bioplastic bags made from corn starch with an attractive style and design.

TUNISIA
Tunisie Telecom
EUR 100m
InnovFin financed the roll-out of 4G mobile network across the country, involving 1500 cellular network sites and 2000km of optic fibre cables.

ISRAEL
Biondvax
EUR 20m
Development of a universal flu vaccine candidate.